PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The primary goal for this trial is to assess the change in PET scans with the administration
of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It has
been established that zoledronate therapy may play a role in delaying and reducing the
incidence of skeletal events. Researchers propose to evaluate the change in the uptake value
of FMAU PET scan after the zoledronate therapy. It has been demonstrated that FMAU PET scans
can successfully demonstrate and detect bony metastatic sites in prostate cancer.
In addition, investigators would like to evaluate the change in the level of the
prostate-specific antigen (PSA) in the patient as well as outcome of bone scans.